Singapore markets closed

GSK Jan 2026 55.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
11.100.00 (0.00%)
As of 11:07AM EDT. Market open.
Full screen
Loading interactive chart…
  • Evening Standard

    FTSE 100 Live 3 June: GSK shares tumble, Monzo turns first profit

    GSK shares are today’s major focus after the drugs giant’s defence against Zantac claims suffered a setback in a Delaware court. The FTSE 100 index is trading higher after Friday’s late rally by Wall Street markets was further boosted by this week’s prospect of an ECB interest rate cut. Other companies in the spotlight today include FTSE 250-listed Hollywood Bowl, having posted an 11% rise in half-year profits.

  • Reuters

    GSK shares tumble 9% after 70,000 Zantac lawsuits allowed to proceed

    (Reuters) -Shares of GSK dropped more than 9% on Monday, after a Delaware judge allowed more than 70,000 lawsuits alleging its discontinued heartburn drug Zantac caused cancer, to go forward, in a blow for the British drugmaker. Its shares were down 9.4% at 16 pounds by 1052 GMT, on course for their worst day since August 2022, with the drop wiping out nearly 7 billion pounds ($8.90 billion) of the company's market value. The lawsuits have been an overhang for the company, with concerns about protracted legal wrangling and compensation wiping almost $40 billion off the combined market value of GSK, Sanofi, Pfizer and Haleon over roughly a week in August 2022.

  • Business Wire

    Belantamab Mafodotin combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma

    PHILADELPHIA, June 02, 2024--Belantamab Mafodotin combo reduced the risk of disease progression or death by nearly 50% versus SOC combo in relapsed/refractory multiple myeloma